Childhood Arthritis Overview

Principles

Definition

Childhood arthritis is a distinct area of medical research dedicated to the study of chronic inflammatory joint diseases and related systemic conditions occurring in the pediatric population. This academic concept investigates the unique biological mechanisms, clinical manifestations, and treatment outcomes pertinent to these conditions in children and adolescents, encompassing their diverse subtypes, heterogeneous etiologies, and long-term impact on development, with the aim of advancing diagnostic and therapeutic strategies.

Ontological type

Subtypes and classification

Treatment strategies

Pathophysiology

Key developments

Key Figures

Pediatric Arthritis Taxonomy era

James W. Varni[1], affiliated with Johns Hopkins University[3] and the University of California, San Diego[4], helped shape pediatric arthritis research in this era. His key contributions included developing standardized pain measures for juvenile rheumatoid arthritis, notably the Varni/Thompson Pediatrie Pain Questionnaire[6], Comprehensive Assessment of Pain in Juvenile Rheumatoid Arthritis: An Empirical Model[7], and Chronic musculoskeletal pain and functional status in juvenile rheumatoid arthritis: an empirical model[8], which enabled consistent phenotyping and informed prognosis and treatment decisions in pediatric arthritis. Alberto Martini[2], affiliated with the University of California, San Diego[4] and Icahn School of Medicine at Mount Sinai[5], contributed to the immunogenetic and inflammatory framework distinguishing pediatric phenotypes in this era. His notable contribution in this era is the 1997 paper Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: A model for stunted growth in children with chronic inflammation[9], which linked inflammatory mediators to growth outcomes and influenced pediatric therapeutic considerations.

Outcome Measurement Standardization era

Marc C. Hochberg [1], whose work in this era included appointments at Harvard University [3] and the University of California, San Francisco [4], contributed to advancing standardized measurement concepts in pediatric rheumatology. His key contribution in this era was helping shape the American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis [5], which established formal guidelines that underpinned multicenter studies and informed outcome assessment in trials. Kenneth G. Saag [2], whose roles included positions at Harvard University [3] and the University of California, San Francisco [4], coauthored the same American College of Rheumatology 2008 recommendations for DMARDs in RA [5]. Together, their collaboration produced guidelines that standardized pharmacologic approaches and facilitated the consistent use of outcome- and quality-of-life measures central to the era.

Biomarker-Guided Precision Therapy era

Sarah Ringold [1] is a leading figure in pediatric arthritis care with affiliations at Harvard University [3] and the University of California, San Francisco [4]. Her key contributions in this era include co-authoring the 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications [6], the 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis [7], and the 2018 Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans [8], which collectively advanced risk stratification, safety practices, and standardized, treat-to-target pathways in biomarker-guided care. Peter A. Nigrović [2] is a prominent figure with affiliations at Harvard University [3] and Boston University [5]. His contributions in this era include co-authoring the 2013 Update [6], the 2019 Guideline [7], and the 2018 CARRA Consensus Treatment Plans [8], promoting standardized, guideline-concordant, and biomarker-informed strategies that facilitated evidence-based biologic use and tapering in juvenile arthritis care.